Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Dealnews2025-11-08T12:38:25+00:00November 8th, 2025|The New York Times|
What Trump’s New Drug Pricing Deal Means for People With Obesitynews2025-11-06T21:53:59+00:00November 6th, 2025|The New York Times|
Cardiovascular Benefits of Wegovy Extend Beyond Weight Loss, Study Showsnews2025-10-22T22:30:06+00:00October 22nd, 2025|The New York Times|
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugsnews2025-10-05T19:47:27+00:00October 5th, 2025|The New York Times|
Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertisernews2025-09-12T22:09:11+00:00September 12th, 2025|The New York Times|
Un fármaco común para perder peso puede tratar una enfermedad hepática grave, según la FDAnews2025-08-19T07:02:57+00:00August 19th, 2025|The New York Times|
Wegovy Gets F.D.A. Approval for MASHnews2025-08-18T17:21:18+00:00August 18th, 2025|The New York Times|
How Ozempic Maker Novo Nordisk Lost Its Shinenews2025-08-07T13:33:20+00:00August 7th, 2025|The New York Times|
Pill Causes Major Weight Loss in Eli Lilly Trial’s Resultsnews2025-08-07T11:37:14+00:00August 7th, 2025|The New York Times|
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drugnews2025-05-12T00:08:25+00:00May 12th, 2025|The New York Times|
